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Abstract 52 
Atopic dermatitis (AD) is a prevalent disease worldwide associated with systemic co-morbidities, 53 
representing a significant burden on individuals, their families and society. Therapeutic options for AD 54 
remain limited, in part due to lack of well-characterised animal models.  To better define 55 
pathophysiological mechanisms and to identify novel therapeutic targets and biomarkers that predict 56 
therapeutic response, there has been increasing interest in developing experimental approaches to study 57 
the pathogenesis of human AD in vivo, in vitro, and in silico.  This review critically appraises a range of 58 
models including: genetic mutations relevant to AD;  experimental challenge of human skin in vivo; tissue 59 
culture models;  integration of “omic” datasets; and the development of predictive computational models. 60 
Whilst no one individual model recapitulates the complex AD pathophysiology, our review highlights 61 
insights gained into key elements of cutaneous biology, molecular pathways and therapeutic target 62 
identification through each approach.  Recent developments in computational analysis, including the 63 
application of machine learning and a systems approach to data integration and predictive modelling, 64 
highlight the applicability of these methods to AD subclassification (endotyping), therapy development and 65 
precision medicine.  Such predictive modelling will highlight knowledge gaps, further inform refinement of 66 
biological models, and support new experimental and systems approaches to AD. 67 
 68 
Key words: Atopic dermatitis, atopic eczema, Endotype, Human models, Machine learning, Mechanistic 69 
models, Precision medicine, Tissue culture models, Skin equivalents, Systems biology 70 
 71 
Abbreviations 72 
ACD   Allergic contact dermatitis 73 
AD   Atopic dermatitis 74 
APT  Atopy Patch Test 75 
ILs   Interleukins 76 
 IRFs   Interferon regulatory factors 77 
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IPEX   Polyendocrinopathy Enteropathy X-linked syndrome 78 
LV   Langerhans cells 79 
PD   Pharmacodynamic 80 
PK   Pharmacokinetic  81 
RAST   Radioallergosorbent test 82 
RNA-Seq  RNA-sequencing 83 
SPT  Skin prick testing  84 
  85 
  86 
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Introduction 87 
Atopic dermatitis (AD; synonym atopic eczema) has a complex aetiology, involving multiple genetic and 88 
environmental factors1 2.  With its very high incidence in childhood, chronicity, devastating effect on quality 89 
of life for affected patients and their families, enormous socio-economic costs, and limited therapeutic 90 
options to date, AD represents a major challenge. Furthermore, there is clear evidence that AD represents a 91 
systemic inflammatory disease with multiple comorbidities extending beyond the well-recognized atopic 92 
associations3. Consequently, a number of animal models have been developed and utilized by investigators 93 
and the pharmaceutical industry to better understand the disease and consider new pathways to target4.  94 
However, as recently reviewed, mouse models do not adequately reflect the transcriptomic and gene 95 
pathways activated in human AD skin5 and the intrinsic difference between mouse and human skin 96 
represents a barrier to direct translation of findings from animals into human disease.  Consequently, there 97 
has been increasing interest in experimental studies in humans (in part facilitated by technological and 98 
“omic” developments), cell culture models utilizing human tissue, and the use of computational or 99 
mathematical models that are developed by integrating these data.  In this review article, we have used the 100 
term “human AD model” to define representations of the disease state and interventions that enable 101 
scientific insight into disease pathogenesis, disease course, and response to therapy.  We  delineate and 102 
critically appraise these AD modelling approaches that range from the experimental study of human skin in 103 
vivo (including challenge studies and detailed phenotyping and investigation of patients harboring specific 104 
genetic mutations), the generation of AD-relevant models using immunological, genetic and molecular 105 
methods in 2D and 3D human tissue culture, to the development of in silico computational models using a 106 
systems biology approach. Whilst a reductionist approach cannot by definition recapitulate the full 107 
spectrum of AD, these models have greatly increased our understanding of the molecular drivers of AD and 108 
provide a powerful tool for preclinical drug development and target validation. However, just as the 109 
etiology, clinical expression, and severity of AD range broadly among patients, in vitro and in silico models 110 
of AD vary widely both in how the AD phenotype is induced and how the models are evaluated. Therefore, 111 
we invited members of the International Eczema Council (IEC; www.eczemacouncil.org), a group of experts 112 
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in AD, and associated authorities in the field to contribute to a scoping and development meeting and 113 
subsequently to evaluate and critically appraise the breadth of human AD and computational models to 114 
determine their strengths and weaknesses in how they recapitulate the pathophysiology of AD and enable 115 
therapeutics to be tested and validated. 116 
 117 
In vivo models of AD 118 
To dissect the pathogenesis of AD, two general approaches using human in vivo models have been followed: 119 
i) the study of rare genetic variants with AD-like phenotypes; and ii) the experimental challenge of AD or 120 
non-AD subjects with allergens or irritants. Regarding the first approach, numerous studies have 121 
characterized genetic disorders that display skin barrier function abnormalities. Most often, these studies 122 
characterized ichthyosis vulgaris, a disease that allowed insights into the function of the epidermal 123 
differentiation gene FLG (encoding filaggrin), in which mutations show the strongest association to AD 124 
development of all known genes6 (Figure 1). Other studies have focused on disorders characterized by 125 
systemic inflammation3 and immunodeficiency with AD-like skin manifestations (Figure 1). One example is 126 
patients suffering from Immunodysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome 127 
that serves as a model to study how systemic imbalances in the Treg population can drive cutaneous AD-128 
like inflammation7. In addition, the link between type 2 immunity, transcription factors such as JAK or STAT, 129 
and high levels of IgE was investigated in immunodeficiency syndromes such as STAT3 and DOCK-8 hyper-130 
IgE syndromes or combined immunodeficiency disorders8, 9. Table S1 lists the main genetic conditions that 131 
have provided insight into AD pathogenesis to date. Whilst the study of rare variants offers the opportunity 132 
to delineate distinct molecular mechanisms and control pathways of a particular phenotype, and thus may 133 
be regarded as “human models of AD”, a limitation of this approach is that not all observed phenomena are 134 
relevant in AD, which is more complex and heterogeneous than monogenic disorders.  135 
 136 
The second in vivo approach to study the pathogenesis of AD is standardized challenge with allergens or 137 
other environmental factors. The most commonly used model is the Atopy Patch Test (APT), an 138 
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epicutaneous challenge of specific allergens dissolved in vehicle10, which has provided insight into the 139 
temporal development of immune phenomena in AD11 (Table S2). Although developed in part to define 140 
clinically relevant reactions to aero-allergens, food allergens and autoantigens12 13 14, it´s validity and 141 
predictive value depend on a variety of factors in the protocol 15 and the APT is not used routinely in clinical 142 
practice.  Experimentally, the APT has provided insights into the the temporal sequence of cutaneous 143 
cellular infiltrates.  Acute skin lesions show a highly reproducible Th2 dominant inflitrate16, although other 144 
cell types including Th17 cells are also present17 18. This Th2 dominance is in sharp contrast to other 145 
inflammatory skin diseases such as psoriasis19, 20. Time course studies have shown that additional immune 146 
cell subsets, such as Th1 and Th22 cells, progressively infiltrate the skin during an ongoing APT reaction, 147 
mirroring the cellular composition of acute versus chronic human AD17 21.  The APT has also been used to 148 
characterize dendritic cells within early lesional AD skin, e.g. Inflammatory dendritic epidermal cells18. 149 
Furthermore, the APT has provided insights on the interaction of microbiota and our immune system, in 150 
particular the role of bacterial-derived superantigens acting as an amplifier of the allergen specific 151 
cutaneous response in AD21, 22 23.   In all these experimental APT studies, the population of AD subjects were 152 
well defined with specific inclusion and exclusion criteria (although the precise definitions of AD varied); in 153 
most studies AD, together with specific IgE to the corresponding allergen used in the APT, was an inclusion 154 
criterion. 155 
 156 
Hapten challenge to induce classical allergic contact dermatitis (ACD) in AD patients has also broadened our 157 
understanding of AD pathogenesis (Table S2). Whether AD patients have an increased risk of ACD remains 158 
controversial and may depend on whether they harbor FLG mutations, which may allowed increased 159 
penetration of allergens. However, attenuated ACD reactions have been reported in AD subjects compared 160 
to controls in a severity-dependent manner 24, 25. This might be due to the fact that haptens induce distinct 161 
immune responses26, with fragrances mimicking the Th2/Th22 dominance of AD while nickel, DNCB, or 162 
imiquimod27 induced Th1/Th17 skewed immune responses. Of note, AD patients show a Th2-skewed ACD 163 
reaction28, and this immune deviation might account for the diminished ACD prevalence in AD. A Th2 164 
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immune reaction profile of AD patients was also observed in an aero-challenge setup29, as well as when 165 
challenging AD patients with physical factors such as hard water30, 31.  166 
 167 
All current challenge models have some limitations (Table S2), as they only represent acute reactions and 168 
the small areas of applications cannot reproduce the intense pruritus and sleep disturbances usually 169 
present in AD.  Furthermore, to date they have not stratified for genetic differences/endotypes amongst AD 170 
patients comparing APTs in patients with and without FLG mutations, for example, might be a useful line of 171 
future investigation.  Moreover, in the future, molecular profiling of lesional skin from standardized 172 
challenge models, adjusted according to AD endotype,  might be used in early clinical studies to evaluate 173 
the potential of new drugs to improve AD32.  174 
 175 
In Vitro Models 176 
As shown in Table S3, there are several 2D cell culture and 3D organotypic models for AD that complement 177 
each other in addressing specific experimental questions. While, 2D cell culture models (by definition) do 178 
not duplicate the architecture of skin, they are amenable to high-throughput techniques for drug discovery 179 
and target validation (2D model section, Supplementary Table S3). Accordingly, Otsuka et al. used 2D 180 
cultures to screen a chemical library for compounds that enhance FLG transcriptional activation and mRNA 181 
expression, suggesting a potential novel therapeutic agent for AD33. On the other hand, 3D models replicate 182 
the stratified, squamous epithelium of epidermis, but require specific expertise and are time consuming. 183 
Epidermal equivalents consist of keratinocytes without a dermal compartment, while skin equivalents have 184 
a dermis, such as fibroblast-embedded collagen (3D model section, Supplementary Table S3). Both 2D and 185 
3D models are amenable to treatment with disease-relevant cytokines, gene knockdown, use of patient-186 
derived cells, and/or co-culture (Figure 2 and Supplementary Table S3).  187 
 188 
 The immune system is a major driver of AD and in vitro immune modulation with disease-relevant 189 
cytokines, such as interleukins (ILs), can lead to AD-like phenotypes in normal primary keratinocytes34 and 190 
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3D models 35-41 (3D cytokine model section, Supplementary Table S3). Knockdown of filaggrin in culture 191 
systems can give insight into the molecular and proteomic changes associated with its loss in AD42; and 192 
combining filaggrin knockdown with other perturbations, e.g., cytokine treatment, can be used to study the 193 
multifactorial drivers of AD. For example, Hönzke et al. reported that filaggrin knockdown exacerbated 194 
epidermal responses to IL-4 and 13, including increased proliferation and keratinocyte-released cytokines in 195 
3D skin equivalents43.  Patient-derived cells for 2D and 3D culture or tissue for explant culture are limited by 196 
access and availability, but may be the most relevant in terms of modeling AD 44-47. Further, patient biopsies 197 
can be a source of skin cells other than keratinocytes, allowing for co-culture models. Given that multiple 198 
systems contribute to AD, co-culture models that include immune cells, dermal fibroblasts, and neurons 199 
can begin to address their interplay with keratinocytes. For example, Berroth et al. derived keratinocytes 200 
and fibroblasts from normal and AD skin and showed that AD-derived fibroblasts are sufficient to decrease 201 
FLG mRNA in normal-derived keratinocytes in 3D culture47. Moreover, combining FLG knockdown with 202 
CD4+ activated T-cells uncovered direct cross-talk between keratinocytes and T-cells that resulted in T-cell 203 
migration within the dermal compartment towards the epidermis 48. These studies highlight the levels of 204 
complexity that can be engineered into the 3D culture models. 3D culture systems have also been used to 205 
understand environmental influences on skin, including air pollution, ultraviolet radiation exposure, and 206 
bacterial infection49-51. These relevant environmental factors could therefore be incorporated into in vitro  207 
models of AD. The 3D cultures and skin explants can also be used to assess the comparative efficacy and 208 
practical applicability of novel drug delivery systems 52, 53. Notably, despite the assorted methodologies 209 
applied in developing in vitro models of AD, there is overlap in the AD-like characteristics amongst the 210 
various models: most produce perturbed epidermal morphology, abnormal differentiation, and barrier 211 
dysfunction. Most often, disparities in reported phenotypes appear to stem, at least in part, from 212 
differences in the methodologies used in evaluating models (not necessarily because of the absence of the 213 
phenotype). 214 
 215 
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Although in vitro models may not mimic certain symptomatic and/or subjective aspects of the disease such 216 
as pruritus and pain, they allow monitoring of changes in epidermal morphology and differentiation, gene 217 
and protein expression, lipid synthesis, and barrier function. Histologically, AD skin sections and most 3D 218 
models of AD show profound changes in the epidermal compartment, including hypogranulosis, spongiosis, 219 
and increased cellularity due to hyperproliferation (3D model section, Supplementary Table S3). Changes in 220 
expression of genes (detected by microarray, RNA-sequencing (RNA-Seq), or qPCR) and protein (detected 221 
by liquid chromatography mass spectrometry, Western blot, ELISA, or immunohistochemistry) can be 222 
used to evaluate disturbances in differentiation and immune response in 2D and 3D models. Lipid synthesis, 223 
which is required for optimal barrier function, can be monitored by expression of related enzymes or 224 
directly by mass spectrometry. Epidermal barrier function can be monitored in 2D and 3D models, 225 
depending on the assay. We recommend that the phenotype of any AD in vitro model should be extensively 226 
characterized, and should include parallel analysis of epidermal morphology, differentiation status, loss or 227 
gain of key transcripts/proteins, analysis of immune components, and assessment of functional epidermal 228 
barrier parameters. Full characterization of any AD model can inform downstream evaluation of potential 229 
therapeutic agents with respect to reversing different aspects of the disease. Testing potential targets or 230 
drugs in several model types can add rigor and indicate if a signaling pathway or protein is central to the 231 
diverse manifestations of AD.  232 
 233 
In silico computational models 234 
A core element of a systems biology approach is development of in silico computational models 235 
(mechanistic models) by integration of different types of experimental and clinical data from multiple 236 
studies, including those associated with disease conditions. In silico experiments, i.e. computer simulations 237 
or mathematical analysis of in silico models, can test model-specific hypotheses, predict disease prognosis 238 
or treatment outcomes, and identify knowledge gaps, guiding future experiments and clinical trials that 239 
produce further data. This iterative process refines in silico models, providing holistic systems-level 240 
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mechanistic insights into how perturbations (treatments or risk factors) lead to whole-organism 241 
phenotypes.  242 
 243 
A mechanistic model describes causative interactions between the system’s components involved in the 244 
phenomena of interest (e.g. disease or treatment outcomes). Existing mechanistic models of AD vary 245 
widely depending on the levels of interactions (tissue, cells, proteins, genes) included in the model and 246 
mathematical methods used to describe the interactions. 247 
 248 
Domínguez-Hüttinger et al. developed a multi-scale deterministic model that delineates interactions 249 
between the environment, skin barrier integrity and immune activation by ordinary differential equations54 250 
(Table 1).  Two bistable “switches” are described – the first regulating the onset of AD flares and the second 251 
controlling progression to severe and persistent disease. The model predicts, for example, that genetic 252 
predisposition to barrier dysfunction (e.g. FLG haploinsufficiency) predisposes to longer flares and more 253 
persistent disease and that prophylactic emollient use may be beneficial (Table 1).  254 
 255 
Application of optimal control theory to the hybrid mathematical model can inform the  design of patient-specific 256 
optimal strategies for “proactive therapy” to prevent recurrent flares once the disease has been brought under initial 257 
control 55.   For example, this computational model supports the need for higher topical steroid treatment 258 
dose after disease worsening and the potential need for more frequent than 2-3 days per week application 259 
of topical steroid treatment to maintain remission56 in patients with FLG haploinsufficiency (Table 1), 260 
presenting a readily testable stratification treatment regime based on genotype.   261 
 262 
Polak et al. developed a stochastic Petri net model that delineates genetic regulatory mechanisms 263 
responsible for immune responses in Langerhans cells (LCs)57 (Table 1). The model describes reported 264 
interactions between interferon regulatory factors (IRFs), IRF transcription partners and DNA sequences in 265 
a logic-based diagram. In vitro experiments validated model predictions that LCs’ ability to present a 266 
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peptide is altered by cytokine milieu and that a PI3Kgamma inhibitor reduces the LCs’ ability to induce Th1 267 
responses. These smaller-scale and focused mechanistic models can describe detailed interactions which 268 
are difficult to be included and validated in multi-scale models. Inclusion of the detailed interactions would 269 
make the multi-scale models too complex to interpret and to be validated, due to the current lack of 270 
quantitative dynamic data that measures the variables across different scales simultaneously.  271 
 272 
Subramanian et al. used a pathway model that included manually-curated skin-specific pathways and 273 
relevant genes58 (Table 1).  Pathway enrichment analysis, using transcriptomic datasets of AD patients, 274 
provided mechanistic insights into drug actions of topical betamethasone and pimecrolimus. The pathway 275 
model would allow in silico experiments, once the kinetics parameters for pathways are identified, to 276 
provide quantitative and dynamic predictions of disease progression and treatment outcomes. 277 
 278 
Population pharmacokinetic and pharmacodynamic (PK/PD) models have also been developed to describe 279 
differences and variability in pharmacological effects observed in large clinical studies for AD treatments59 280 
60. The authors identified the model parameters that can best fit to the effects of nemolizumab and 281 
dupilumab measured in terms of AD severity score or pharmacokinetics (Table 1) 59 60. Population PK/PD 282 
models could help achieve mechanistic understanding of pharmacological effects, if combined with 283 
mechanistic models. 284 
 285 
One of the challenges in developing mechanistic models is identification of the components and the 286 
pathways that are relevant to the model-specific hypothesis to be tested. This can be achieved by unbiased 287 
multivariate analyses of a collection of large-scale data, for example by machine learning data analysis. 288 
Application of machine learning methods to AD-related data is relatively limited at present, but some 289 
relevant works have been already published. Thijs et al. developed a piecewise linear mixed model to 290 
predict AD severity scores after different treatments61 and Kiiski et al. developed a multivariate logistic 291 
regression model to predict a “good treatment response” 62.  A sufficient level of cross-validation is crucial 292 
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to reduce bias and to ensure the general applicability of models that have predictive power beyond mere 293 
description of data. 294 
All the models presented above were developed based on the published data derived from studies in which 295 
the inclusion and exclusion criteria for AD were specified.  Whilst the majority of studies utilised the Hanifin 296 
and Rajka criteria and specified further clinical (including co-morbidities) and demographical details, it is 297 
clear that patients with AD present with a wide spectrum of clinical and molecular features (including for 298 
example a greater heterogeneity in transcriptomic profile of lesional skin compared to psoriasis)63.   299 
 300 
Future developments 301 
The development of more sophisticated human models of AD that integrate large scale clinical and ‘omic’ 302 
data offer the potential for a deeper understanding of disease endotypes, molecular mechanisms 303 
underlying key pathogenic events and clinical hallmarks of AD, as well as prediction of therapeutic 304 
outcomes, including comorbidity at the level of an individual patient.  Accepting that, by definition, these 305 
human models are based upon a reductionist approach, they need to reflect the complexity of AD 306 
pathogenesis, including epidermal barrier dysfunction, altered penetration of chemicals and allergens, 307 
host/environment interaction, type 2 immunity, and tissue remodeling. We have illustrated in this review 308 
that the main approaches available today are in vitro models, identification and characterization of human 309 
inherited syndromes resembling AD, in vivo challenges of AD patients, as well as in silico models. Here, we 310 
speculate how the future of AD research will likely inform the development of more refined human models 311 
of AD. 312 
 313 
Refinement is likely to depend, at least in part, upon methodological advances in the field and the 314 
additional information generated by novel approaches.  For example, single cell sequencing has recently 315 
identified novel rare but important immunological subsets64 and intravital photon microscopy has enabled 316 
visualization of cell-cell communication during  inflammation65 66. Application of this technology to AD is 317 
likely to  inform the inclusion of distinct epithelial and immune cell types64 and/or genetically modified 318 
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primary human cells67. Furthermore, small-scale spheroid organoids may enhance high-throughput 319 
approaches in the field68. Finally, we expect that a technological breakthrough in the development of three-320 
dimensional skin models will be facilitated by cell printers69, 70.   321 
 322 
Deep neural networks are being applied as artificial intelligence tools to facilitate physician interpretation 323 
in the field of melanoma diagnostics 71 and increasingly as methods to enable large data set integration. 324 
The first examples of disease classifiers72 and prediction of disease severity from biomarker sets61, 73, 74 have 325 
recently been published, and we expect this line of development to continue while ensuring a sufficient 326 
level of validation. We anticipate that refinement of these methods, in combination with in silico models, 327 
may lead to computational approaches and predictive models applied to diagnostics and therapeutic 328 
stratification. The descriptive disease ontology of inflammatory skin diseases will need to be revised by 329 
shifting to pathogenesis-oriented structure75  and, in the future, by better definition of disease endotypes 330 
based on integration of multiomics data, clinical features, and clinical response to therapy in light of in silico 331 
models as assessed in large-scale and longitudinal cohorts76.  These advances are likely to inform the 332 
development of many of the current models. 333 
 334 
To achieve a substantial breakthrough, though, we expect that different approaches will need to be 335 
combined, integrated, standardized, and performed at larger scale (Figure 3). For example, observations 336 
made in rare human disease variants or by specific challenge models in AD patients may be validated in 337 
vitro and mapped to disease signatures in silico. Validation of functional hypotheses will increasingly 338 
depend upon cross-referencing of data derived from clinical samples with outputs from in vitro models. 339 
Integration of clinical, biomarker, PK/PD (topical and/or systemic) and clinical outcome data will inform 340 
therapy development and precision medicine. Notably, all of our models depend on how precisely a 341 
particular question is asked and the quality of the clinical input, including the clinical metadata and 342 
integration with omics data derived from clinical samples.  Finally, advanced statistical and machine 343 
learning analysis combined with in silico predictive modelling will be required to integrate information 344 
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throughout all described layers and data sets to elucidate underlying mechanisms (and endotypes), further 345 
highlighting the importance of data standardization and scientific networking.  346 
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Figure legends 357 
 358 
Figure 1. Diagrammatic representation of ‘Human knockout’ monogenic models providing insight into the 359 
pathomechanisms of AD. Specific genetic variants affecting the structural and/or immune functions of skin 360 
or other organs recapitulate features, but not the entire phenotype, of atopic inflammation and AD. 361 
CARD11, caspase recruitment domain-containing protein 11; CDSN, corneodesmosin; CTLA4, cytotoxic T 362 
lymphocyte-associated protein 4;  DOCK8, dedicator of cytokinesis 8; DSG1, desmoglein 1; DSP, 363 
desmoplakin; FLG, filaggrin; FOXP3, forkhead-box-protein 3; IL2RA, interleukin-2 receptor alpha; IL4RA, 364 
interleukin 4 receptor alpha; IFNGR1, interferon gamma receptor 1; MALT1, mucosa-associated lymphoid 365 
tissue lymphoma translocation protein 1; PGM3, phosphoglucomutase 3; RAG1, RAG2, recombination-366 
activated gene 1 and 2; SPINK5, serine protease inhibitor Kazal type 5; STAT3, signal transducer and 367 
activator of transcription 3. 368 
 369 
Figure 2. Human in vitro models of AD. In vitro models can be designed to address specific experimental 370 
questions based on the input materials of the cultures. Assessment of the cultures, or output, depends on 371 
the type of culture. HEE, human epidermal equivalent; HSE, human skin equivalent (inset: fibroblasts in 372 
collagen); FLG, filaggrin; IVL, involucrin; KRT10, keratin 10; DSG1, desmoglein 1;  CDSN, corneodesmosin; 373 
TSLP, thymic stromal lymphopoietin; TEER, trans-epithelial electrical resistance. 374 
 375 
Figure 3. Interconnected multi-layer networks: the future of human AD modelling. To answer clinically 376 
relevant questions such as identification of distinct disease endotypes, elucidation of molecular 377 
pathomechanisms, or prediction of therapeutic response, a combination of innovative in vitro and in silico 378 
models obtained by a systems biology approach and machine learning algorithms will be needed. 379 
 380 
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Table 1 384 
Model 
Type 
Scientific Merits  Clinical Utility  Limitations Key Features  
 
Key Findings/Predictions  Refs 
Multi-scale 
mechanistic 
model 
Mechanistic 
understanding of 
system-level 
effects of 
potential triggers 
and processes on 
disease state  
Identification of 
therapeutic 
targets, and 
their 
mechanisms, for 
further clinical 
investigation. 
Prediction of 
dynamic effects 
of therapeutics, 
leading to 
patient 
stratification  
Models 
developed 
based on 
hypothesized 
relationships 
that were 
previously 
described 
experimentally.  
A hybrid ordinary differential 
equation model of the 
dynamic interplay between 
skin barrier function, 
immune responses and 
environmental stressors that 
determines AD pathogenesis 
Preventive effects of emollients 
against AD progression (shown 
by clinical trials). Synergistic 
effects of environmental (eg. 
microbiome) and genetic (eg. 
FLG) risk factors on AD 
progression (shown by mice 
experiments with ovalbumin 
challenge or dose-dependent 
effects of FLG deficiency) 
54
 
A hybrid model of treatment 
effects of corticosteroids and 
emollients on AD 
pathogenesis and 
exploration of optimal 
regimes for induction of 
remission and maintance of 
remission 
Poor adherence to the suggested 
optimal treatment schedule 
leads to higher treatment doses. 
Application of corticosteroids for 
2 consecutive days per week is 
optimal for maintenance period 
55
 
Gene 
regulatory 
network 
model 
Understanding of 
gene regulatory 
mechanisms 
behind disease 
processes 
Identification of 
therapeutic 
targets, and 
their 
mechanisms, at 
the gene 
regulation level.  
Models 
developed 
based on 
published 
genetic 
interactions.  
Stochastic Petri Net model of 
Interferon regulatory factors 
gene regulatory network in 
response to in vitro 
treatment of Langerhans 
cells (LC) with TNFα and TSLP 
In vitro experiments validated 
predictions that LCs’ ability to 
present a peptide is altered by 
cytokine milieu and that PI3Kg 
inhibitor reduces the LC’s ability 
to induce Th1 responses  
57
 
Pathway 
models 
Understanding of 
disease 
mechanisms 
Identification of 
therapeutic 
targets, and 
their 
mechanisms 
Models 
developed 
based on 
published 
pathways. 
A pathway model including 
35 manually-curated skin-
specific pathways and 2600+ 
genes.  
Pathway enrichment analysis 
using transcriptomic datasets of 
10 AD patients treated with 
betamethasone valerate and 
pimecrolimus predicted 
mechanism of action of both 
drugs on human skin 
58
 
Population 
PK/PD 
models 
Understanding of 
differences and 
variability in 
pharmacological 
effects among a 
target population 
from clinical trials 
data 
Prediction of 
optimal dose 
regimen. Testing 
effects of weight, 
gender etc. 
Requires a 
large clinical 
data to have 
sufficient 
predictive 
power 
 
PK/PD model for serum 
nemolizumab and pruritus 
VAS developed from 299 
patients’ time course data 
An appropriate flat dose 
regimen that is independent of 
body weights 
59
 
Two compartment PK model 
for dupilumab developed 
from data of 197 healthy 
volunteers and AD patients 
from 6 studies 
Production rate of IL4Ra is 
similar for AD patients and 
normal volunteers, and does 
not change over time 
60
 
Machine 
learning 
predictive 
models 
Unbiased analyses 
of differences 
between disease 
and non-disease 
(including 
treated) tissue/ 
patients and 
prediction of 
clinical outcomes 
(prognostic and 
therapeutic) 
Identification of 
disease and 
therapeutic 
targets. Findings 
can feed into 
mechanistic 
models 
Causative 
mechanisms 
remain largely 
unknown.  
Machine 
learning 
applications to 
atopic eczema 
relatively 
limited at 
present 
Piecewise linear mixed 
models to predict EASI scores 
at 3 future timepoints from 
baseline biomarkers. 
Developed from data of 150 
serum biomarkers measured 
in 193 AD patients   
Combination of TARC, IL-22 and 
sIL-2R provides a good predictor 
for future EASI  
61
 
 
Multivariate logistic 
regression model to identify 
predictors of long-term 
response to topical 
maintenance treatment in AD 
on 169 patients. 
Serum total IgE (rather than the 
initial severity) is the most 
important factor predicting a 
good long-term treatment 
outcome 
62
 
 385 
 386 
 387 
  388 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
References 389 
 390 
1. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-391 
wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic 392 
dermatitis. Nat Genet 2015; 47:1449-56. 393 
2. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109-22. 394 
3. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing 395 
Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. J Invest Dermatol 2017; 396 
137:18-25. 397 
4. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009; 398 
129:31-40. 399 
5. Ewald DA, Noda S, Oliva M, Litman T, Nakajima S, Li X, et al. Major differences between human 400 
atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J 401 
Allergy Clin Immunol 2017; 139:562-71. 402 
6. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N 403 
Engl J Med 2011; 365:1315-27. 404 
7. Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up 405 
of IPEX syndrome patients after different therapeutic strategies: An international multicenter 406 
retrospective study. J Allergy Clin Immunol 2018; 141:1036-49 e5. 407 
8. Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and 408 
genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol 2018; 409 
141:1450-8. 410 
9. Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, et al. Atopic dermatitis, STAT3- 411 
and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014; 69:943-53. 412 
10. Turjanmaa K, Darsow U, Niggemann B, Rance F, Vanto T, Werfel T. EAACI/GA2LEN position paper: 413 
present status of the atopy patch test. Allergy 2006; 61:1377-84. 414 
11. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and 415 
molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 416 
138:336-49. 417 
12. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema 418 
with the atopy patch test: a randomized, double-blind multicenter study. Atopy Patch Test Study 419 
Group. J Am Acad Dermatol 1999; 40:187-93. 420 
13. Schmid-Grendelmeier P, Fluckiger S, Disch R, Trautmann A, Wuthrich B, Blaser K, et al. IgE-mediated 421 
and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J 422 
Allergy Clin Immunol 2005; 115:1068-75. 423 
14. Ungar B, Correa da Rosa J, Shemer A, Czarnowicki T, Estrada YD, Fuentes-Duculan J, et al. Patch 424 
testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. Exp 425 
Dermatol 2017; 26:272-5. 426 
15. Darsow U, Vieluf D, Ring J. Atopy patch test with different vehicles and allergen concentrations: an 427 
approach to standardization. J Allergy Clin Immunol 1995; 95:677-84. 428 
16. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C. House dust mite-specific T cells in the skin 429 
of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J 430 
Allergy Clin Immunol 1992; 89:801-10. 431 
17. Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive 432 
activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and 433 
chronic atopic dermatitis. J Allergy Clin Immunol 2012; 130:1344-54. 434 
18. Kerschenlohr K, Decard S, Przybilla B, Wollenberg A. Atopy patch test reactions show a rapid influx 435 
of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients 436 
with intrinsic atopic dermatitis. J Allergy Clin Immunol 2003; 111:869-74. 437 
19. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and 438 
psoriasis--part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011; 439 
127:1420-32. 440 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, et al. Mutual antagonism of T 441 
cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365:231-8. 442 
21. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, et al. IL-17 in atopic eczema: 443 
linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin 444 
Immunol 2009; 123:59-66 e4. 445 
22. Niebuhr M, Scharonow H, Gathmann M, Mamerow D, Werfel T. Staphylococcal exotoxins are 446 
strong inducers of IL-22: A potential role in atopic dermatitis. J Allergy Clin Immunol 2010; 447 
126:1176-83 e4. 448 
23. Langer K, Breuer K, Kapp A, Werfel T. Staphylococcus aureus-derived enterotoxins enhance house 449 
dust mite-induced patch test reactions in atopic dermatitis. Exp Dermatol 2007; 16:124-9. 450 
24. Hamann CR, Hamann D, Egeberg A, Johansen JD, Silverberg J, Thyssen JP. Association between 451 
atopic dermatitis and contact sensitization: A systematic review and meta-analysis. Journal of the 452 
American Academy of Dermatology 2017; 77:70-8. 453 
25. Correa da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, et al. Patients with 454 
atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common 455 
allergens in skin. J Allergy Clin Immunol 2015; 135:712-20. 456 
26. Dhingra N, Shemer A, Correa da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, et al. Molecular 457 
profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J 458 
Allergy Clin Immunol 2014; 134:362-72. 459 
27. Garzorz-Stark N, Lauffer F, Krause L, Thomas J, Atenhan A, Franz R, et al. Toll-like receptor 7/8 460 
agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in 461 
human subjects. J Allergy Clin Immunol 2018; 141:1320-33 e11. 462 
28. Newell L, Polak ME, Perera J, Owen C, Boyd P, Pickard C, et al. Sensitization via healthy skin 463 
programs Th2 responses in individuals with atopic dermatitis. J Invest Dermatol 2013; 133:2372-80. 464 
29. Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A, et al. Exacerbation of atopic 465 
dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 466 
2015; 136:96-103 e9. 467 
30. Engebretsen KA, Bager P, Wohlfahrt J, Skov L, Zachariae C, Nybo Andersen AM, et al. Prevalence of 468 
atopic dermatitis in infants by domestic water hardness and season of birth: Cohort study. J Allergy 469 
Clin Immunol 2017; 139:1568-74 e1. 470 
31. Engebretsen KA, Kezic S, Jakasa I, Hedengran A, Linneberg A, Skov L, et al. Effect of atopic skin 471 
stressors on natural moisturizing factors and cytokines in healthy adult epidermis. Br J Dermatol 472 
2018. 473 
32. Guttman-Yassky E, Ungar B, Malik K, Dickstein D, Suprun M, Estrada YD, et al. Molecular signatures 474 
order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. J 475 
Allergy Clin Immunol 2017; 140:1032-42 e13. 476 
33. Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, et al. Possible new therapeutic 477 
strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin 478 
Immunol 2014; 133:139-46.e1-10. 479 
34. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of 480 
atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009; 124:R7-r12. 481 
35. Kamsteeg M, Bergers M, de Boer R, Zeeuwen PL, Hato SV, Schalkwijk J, et al. Type 2 helper T-cell 482 
cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin 483 
equivalent. Am J Pathol 2011; 178:2091-9. 484 
36. Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired Tight Junctions in Atopic 485 
Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17. PLoS One 2016; 486 
11:e0161759. 487 
37. Hanel KH, Pfaff CM, Cornelissen C, Amann PM, Marquardt Y, Czaja K, et al. Control of the Physical 488 
and Antimicrobial Skin Barrier by an IL-31-IL-1 Signaling Network. J Immunol 2016; 196:3233-44. 489 
38. Rouaud-Tinguely P, Boudier D, Marchand L, Barruche V, Bordes S, Coppin H, et al. From the 490 
morphological to the transcriptomic characterization of a compromised three-dimensional in vitro 491 
model mimicking atopic dermatitis. Br J Dermatol 2015; 173:1006-14. 492 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
39. De Vuyst E, Giltaire S, Lambert de Rouvroit C, Malaisse J, Mound A, Bourtembourg M, et al. Methyl-493 
beta-cyclodextrin concurs with interleukin (IL)-4, IL-13 and IL-25 to induce alterations reminiscent 494 
of atopic dermatitis in reconstructed human epidermis. Exp Dermatol 2018; 27:435-7. 495 
40. Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-alpha and Th2 496 
cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum 497 
corneum lipids in human skin equivalents. J Invest Dermatol 2014; 134:1941-50. 498 
41. Nygaard U, van den Bogaard EH, Niehues H, Hvid M, Deleuran M, Johansen C, et al. The "Alarmins" 499 
HMBG1 and IL-33 Downregulate Structural Skin Barrier Proteins and Impair Epidermal Growth. Acta 500 
Derm Venereol 2017; 97:305-12. 501 
42. Elias MS, Long HA, Newman CF, Wilson PA, West A, McGill PJ, et al. Proteomic analysis of filaggrin 502 
deficiency identifies molecular signatures characteristic of atopic eczema. J Allergy Clin Immunol 503 
2017; 140:1299-309. 504 
43. Honzke S, Wallmeyer L, Ostrowski A, Radbruch M, Mundhenk L, Schafer-Korting M, et al. Influence 505 
of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and ss-Defensins in Filaggrin-506 
Deficient Skin Equivalents. J Invest Dermatol 2016; 136:631-9. 507 
44. Pastore S, Fanales-Belasio E, Albanesi C, Chinni LM, Giannetti A, Girolomoni G. Granulocyte 508 
macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. 509 
Implications for sustained dendritic cell activation in the skin. J Clin Invest 1997; 99:3009-17. 510 
45. van Drongelen V, Danso MO, Out JJ, Mulder A, Lavrijsen AP, Bouwstra JA, et al. Explant cultures of 511 
atopic dermatitis biopsies maintain their epidermal characteristics in vitro. Cell Tissue Res 2015; 512 
361:789-97. 513 
46. Bogiatzi SI, Fernandez I, Bichet JC, Marloie-Provost MA, Volpe E, Sastre X, et al. Cutting Edge: 514 
Proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production 515 
by human skin keratinocytes. J Immunol 2007; 178:3373-7. 516 
47. Berroth A, Kuhnl J, Kurschat N, Schwarz A, Stab F, Schwarz T, et al. Role of fibroblasts in the 517 
pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2013; 131:1547-54. 518 
48. Wallmeyer L, Dietert K, Sochorova M, Gruber AD, Kleuser B, Vavrova K, et al. TSLP is a direct trigger 519 
for T cell migration in filaggrin-deficient skin equivalents. Sci Rep 2017; 7:774. 520 
49. Lecas S, Boursier E, Fitoussi R, Vie K, Momas I, Seta N, et al. In vitro model adapted to the study of 521 
skin ageing induced by air pollution. Toxicol Lett 2016; 259:60-8. 522 
50. Maboni G, Davenport R, Sessford K, Baiker K, Jensen TK, Blanchard AM, et al. A Novel 3D Skin 523 
Explant Model to Study Anaerobic Bacterial Infection. Front Cell Infect Microbiol 2017; 7:404. 524 
51. Marionnet C, Pierrard C, Lejeune F, Sok J, Thomas M, Bernerd F. Different oxidative stress response 525 
in keratinocytes and fibroblasts of reconstructed skin exposed to non extreme daily-ultraviolet 526 
radiation. PLoS One 2010; 5:e12059. 527 
52. Abaci HE, Guo Z, Doucet Y, Jackow J, Christiano A. Next generation human skin constructs as 528 
advanced tools for drug development. Exp Biol Med (Maywood) 2017; 242:1657-68. 529 
53. Castex-Rizzi N, Galliano MF, Aries MF, Hernandez-Pigeon H, Vaissiere C, Delga H, et al. In vitro 530 
approaches to pharmacological screening in the field of atopic dermatitis. Br J Dermatol 2014; 170 531 
Suppl 1:12-8. 532 
54. Dominguez-Huttinger E, Christodoulides P, Miyauchi K, Irvine AD, Okada-Hatakeyama M, Kubo M, 533 
et al. Mathematical modeling of atopic dermatitis reveals "double-switch" mechanisms underlying 534 
4 common disease phenotypes. J Allergy Clin Immunol 2017; 139:1861-72.e7. 535 
55. Christodoulides P, Hirata Y, Dominguez-Huttinger E, Danby SG, Cork MJ, Williams HC, et al. 536 
Computational design of treatment strategies for proactive therapy on atopic dermatitis using 537 
optimal control theory. Philos Trans A Math Phys Eng Sci 2017; 375. 538 
56. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive 539 
treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic 540 
review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164:415-28. 541 
57. Polak ME, Ung CY, Masapust J, Freeman TC, Ardern-Jones MR. Petri Net computational modelling 542 
of Langerhans cell Interferon Regulatory Factor Network predicts their role in T cell activation. Sci 543 
Rep 2017; 7:668. 544 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
58. Subramanian I, Singh VK, Jere A. Elucidating mechanistic insights into drug action for atopic 545 
dermatitis: a systems biology approach. BMC Dermatol 2018; 18:3. 546 
59. Saito T, Iida S, Terao K, Kumagai Y. Dosage Optimization of Nemolizumab Using Population 547 
Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation. J Clin 548 
Pharmacol 2017; 57:1564-72. 549 
60. Kovalenko P, DiCioccio AT, Davis JD, Li M, Ardeleanu M, Graham N, et al. Exploratory Population PK 550 
Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Ralpha, in Atopic 551 
Dermatitis Patients and Normal Volunteers. CPT Pharmacometrics Syst Pharmacol 2016; 5:617-24. 552 
61. Thijs JL, Drylewicz J, Fiechter R, Strickland I, Sleeman MA, Herath A, et al. EASI p-EASI: Utilizing a 553 
combination of serum biomarkers offers an objective measurement tool for disease severity in 554 
atopic dermatitis patients. J Allergy Clin Immunol 2017; 140:1703-5. 555 
62. Kiiski V, Karlsson O, Remitz A, Reitamo S. High Serum Total IgE Predicts Poor Long-term Outcome in 556 
Atopic Dermatitis. Acta Dermato Venereologica 2015; 95:943-7. 557 
63. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or 558 
one spectrum? Curr Opin Immunol 2017; 48:68-73. 559 
64. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals 560 
new types of human blood dendritic cells, monocytes, and progenitors. Science 2017; 356. 561 
65. Reber LL, Sibilano R, Starkl P, Roers A, Grimbaldeston MA, Tsai M, et al. Imaging protective mast 562 
cells in living mice during severe contact hypersensitivity. JCI Insight 2017; 2. 563 
66. Dudeck J, Medyukhina A, Frobel J, Svensson CM, Kotrba J, Gerlach M, et al. Mast cells acquire 564 
MHCII from dendritic cells during skin inflammation. J Exp Med 2017; 214:3791-811. 565 
67. Niehues H, Bouwstra JA, El Ghalbzouri A, Brandner JM, Zeeuwen P, van den Bogaard EH. 3D skin 566 
models for 3R research: The potential of 3D reconstructed skin models to study skin barrier 567 
function. Exp Dermatol 2018; 27:501-11. 568 
68. Lauffer F, Jargosch M, Krause L, Garzorz-Stark N, Franz R, Roenneberg S, et al. Type I Immune 569 
Response Induces Keratinocyte Necroptosis and Is Associated with Interface Dermatitis. J Invest 570 
Dermatol 2018. 571 
69. Kim BS, Kwon YW, Kong JS, Park GT, Gao G, Han W, et al. 3D cell printing of in vitro stabilized skin 572 
model and in vivo pre-vascularized skin patch using tissue-specific extracellular matrix bioink: A 573 
step towards advanced skin tissue engineering. Biomaterials 2018; 168:38-53. 574 
70. Pourchet LJ, Thepot A, Albouy M, Courtial EJ, Boher A, Blum LJ, et al. Human Skin 3D Bioprinting 575 
Using Scaffold-Free Approach. Adv Healthc Mater 2017; 6. 576 
71. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of 577 
skin cancer with deep neural networks. Nature 2017; 542:115-8. 578 
72. Quaranta M, Knapp B, Garzorz N, Mattii M, Pullabhatla V, Pennino D, et al. Intraindividual genome 579 
expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci Transl Med 580 
2014; 6:244ra90. 581 
73. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An Integrated Model of 582 
Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol 2017; 583 
137:603-13. 584 
74. Krause L, Mourantchanian V, Brockow K, Theis FJ, Schmidt-Weber CB, Knapp B, et al. A 585 
computational model to predict severity of atopic eczema from 30 serum proteins. J Allergy Clin 586 
Immunol 2016; 138:1207-10 e2. 587 
75. Eyerich K, Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. J 588 
Eur Acad Dermatol Venereol 2018; 32:692-703. 589 
76. Paternoster L, Savenije OEM, Heron J, Evans DM, Vonk JM, Brunekreef B, et al. Identification of 590 
atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol 591 
2018; 141:964-71. 592 
 593 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Input Output
Patient-derived 
tissue/cells: immune, 
keratinocytes, etc.
Normal
Keratinocytes:
primary/immortalized
Gene (e.g., FLG)
knockdown:
siRNA/shRNA/CRISPR
Cytokine
treatment:
interleukin(s)
Co-Culture:
T-cells, neurons, 
fibroblasts
In Vitro Model
2D HEE
HSE Explant
Barrier Function:
Lipid profile, TEER, 
permeability
Epidermal 
Morphology:
e.g., spongiosis
Differentiation:
FLG, IVL, KRT10, LOR, 
DSG1, CDSN, etc.
Key Transcript and 
Protein Changes 
immune, barrier, etc.
Keratinocyte / 
immune cell factors: 
TSLP,  Th2 cytokines
1
d
a
b
e
c
4
2
5
3
a
b
c
d
a
b
e
c
4
2
5
3
d
e
1
d
a
b
e
c
4
2
5
3
1
d
e
4
2
5
3
1
2
3
4
5
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Integrative predictive 
models In vitro modelsIn silico models
Molecular
Mechanisms
Drug 
Endotypes
Disease/ 
Prognostic 
Endotypes
Integration of data by systems biology and machine learning
type 2 
cytokines
AMP´s
S. aureus
Th17/22
Inflammasome
Epidermal 
barrier
IL-31
Neuro-
inflammation
Hapten/ 
allergen
Dendritic
cells
Mast cells
(Auto-) 
IgE
Self-
limited
Progressive
Relapsing-
remitting
Allergic
asthma
Inflammatory
bowel disease
Allergy
Rhino-
conjunctivitis
Responder
prediction
Secondary loss
of efficacy
Risk of
adverse
events
Treatment of
comorbidity
Preclinical
efficacy
prediction
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Genetic disease models of AD 
Genetic disease Gene and mutation type(s) Phenotype(s) Mechanistic insights Clinical utility    Limitations Pathway relevance 
for drug 
development 
Refs. 
Skin barrier 
dysfunction 
       
 
Ichthyosis vulgaris (IV) 
 
 
 
 
 
Generalised peeling 
skin 
 
 
 
AD and eczema 
herpeticum 
 
 
Netherton syndrome 
 
 
FLG 
Loss of function mutations 
semi-dominant in IV and 
complex trait in AD 
 
 
CDSN 
Loss of function mutation 
autosomal recessive 
 
 
IFNGR1 
Loss of function mutation 
Complex trait 
 
SPINK5 
Loss of function mutation 
Autosomal recessive 
 
 
Early onset, severe and persistent AD with & 
without other atopic diseases; predisposition to 
eczema herpeticum (EH) 
 
 
 
Ichthyosiform erythroderma, pruritus and food 
allergies 
 
 
 
AD and eczema herpeticum (EH) 
 
 
 
Congenital ichthyosis, severe atopic disease, 
elevated IgE, hypereosinophilia, infections 
 
Understanding that skin barrier dysfunction 
predates atopic inflammation 
 
 
 
 
Confirms the role of corneodesmosin in 
epidermal adhesion 
 
 
 
Defective systemic IFN-gamma immune 
response accounts for disseminated viral skin 
infections 
 
Single nucleotide variants associated with AD. 
Illustrates role of epidermal protease 
inhibitors and kallikrein proteases in 
regulating epidermal barrier function 
 
Illustrates importance of 
barrier repair 
 
 
 
 
Understanding that skin 
barrier dysfunction predates 
atopic inflammation 
 
Helps to explain why a 
subset of AD patients suffer 
recurrent EH 
 
Understanding that skin 
barrier dysfunction predates 
atopic inflammation 
 
 
Molecular mechanisms and 
control pathways remain 
unclear 
 
 
 
 
 
 
 
 
Does not explain all cases of 
EH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protease inhibitors 
 
1, 2
 
 
 
 
 
 
3
 
 
 
 
 
4
 
 
 
 
5
 
Systemic atopic inflammation  
 
     
 
 
Atopic disease 
 
 
 
Severe atopic disease 
 
 
 
 
 
IL4RA 
Gain of function 
Complex trait 
 
CARD11 
Heterozygous mutations  
Loss of function and 
dominant negative effect 
 
Elevated IgE with & without AD  
 
 
 
Severe AD with & without infection 
 
Mutation found in severe cases is also a 
common risk allele in the population 
 
 
Illustrates importance of lymphocyte 
receptor signalling 
 
Evidence of role for IL-4 in 
atopic inflammation 
 
 
mTORC1 and IFN-gamma 
production defects can be 
partially rescued by 
glutamine supplementation 
 
 
 
 
 
Unclear whether this 
mechanism plays a role in 
prevalent AD 
 
IL-4RA 
 
 
 
NFKB and MALT1 
 
6
 
 
 
 
7
 
Skin inflammation and gastrointestinal inflammation       
 
 
SAM (Severe 
dermatitis, multiple 
Allergies and 
Metabolic wasting) 
 
SAM 
 
 
 
DSG1 
Homozygous loss of 
function mutations 
 
 
DSP 
Heterozygous mutation 
 
 
Ichthyosiform erythroderma, atopic disease and 
failure to thrive 
 
 
 
Ichthyosiform erythroderma, atopic disease and 
failure to thrive 
 
DSG1 mutations lead to loss of cell-cell 
adhesion in epidermis 
 
 
 
DSP mutations result in disrupted keratin 
filament attachment to desmosomes 
 
Structural epidermal defects 
lead to atopic inflammation 
 
 
Structural epidermal defects 
lead to atopic inflammation 
 
 
 
 
 
 
 
Other DSP mutations cause 
different phenotypes without 
atopic manifestations 
 
  
8
 
 
 
 
 
9
 
Immunodeficiency syndromes       
 
 
Hyper-IgE 
 
 
 
 
 
 
 
Omenn syndrome 
 
 
 
 
 
Hyper-IgE like 
syndrome 
 
 
Wiskott-Aldrich 
 
 
  
IPEX and IPEX-like 
syndromes 
 
STAT3 
Dominant negative 
mutations 
 
DOCK8 
Autosomal recessive loss of 
function mutations 
 
Hypomorphic missense 
mutations in a range of 
genes involved T and B cell 
development eg. RAG1, 
RAG2 
 
PGM3 
Autosomal recessive loss of 
function mutations 
 
WAS 
X-linked mutations 
 
 
FOXP3, MALT1, IL2RA, 
CTLA-4  
Autosomal recessive 
 
AD-like skin inflammation, elevated IgE, 
immunodeficiency leading to infection 
 
 
AD-like skin inflammation, elevated IgE, 
immunodeficiency leading to infection 
 
 
AD-like skin inflammation, elevated IgE, 
immunodeficiency leading to infection 
 
 
 
 
AD-like skin inflammation, atopy, immune 
deficiency, autoimmunity and neurocognitive 
impairment 
 
AD-like skin inflammation, severe 
immunodeficiency, autoimmunity and 
malignancy 
 
Immune dysregulation, polyendocrinopathy, 
enteropathy and AD-like skin inflammation 
 
 
Illustrates role of STAT3 in signal transduction 
for multiple cytokines 
 
 
Aberrations of T cell and NK cell migration to 
skin can cause atopic inflammation 
 
 
Skin inflammation can occur in the absence of 
adaptive immunity, also seen in mice 
 
 
 
 
Role of glycosylation in immune regulation 
and systemic atopy 
 
 
Systemic imbalances in Treg populations can 
drive cutaneous AD like inflammation 
 
 
Role of autoimmunity in AD-like inflammation 
 
Biologic treatments 
targeting IgE have limited 
clinical efficacy for AD 
 
Antiviral and antibacterial 
prophylaxis, 
immunoglobulin 
replacement and HSCT 
 
 
 
 
 
 
 
 
 
 
Requires HSCT 
 
 
 
Immunosuppressive 
treatment or HSCT 
 
Immunodeficiency is not a 
prominent feature of AD 
 
STAT6: downstream 
of JAKs in Th2 
inflammation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OX40 
 
 
 
FOXP3 as possible 
target for gene 
editing 
 
10
 
 
 
 
11
 
 
 
 
12
 
 
 
 
 
13
 
 
 
 
 
14
 
 
 
 
15, 16
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Table S2. Human In vivo Models of AD 
Atopy Patch Test System Interplay/ 
Application 
Key Findings Scientific Merit/ 
Clinical Relevance 
Limitations Reproducibility Refs. 
APT: clinical usage 
 
 Reviewed in: EAACI position paper     (2) 
 
 
Epidemiology 
 
 
 
Validity/relevance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproducibility 
 
 
Frequency of patch test reactions to 
inhalant allergens in AD patients (n=56) 
 
Comparison of APT and SPT in children 
with AD (n=253) 
 
Comparison of APT and LTT in AD 
patients (n=96) 
 
 
Comparing AD groups: with and w/o 
clinical symptoms (n=79) 
 
 
Comparing APT, SPT, and sIgE with food 
challenge in children with AD 
 
 
Reproducibility of APT reactions in AD 
patients (n=16) 
 
Different vehicles and allergen 
concentrations (AD patients) 
 
 
 
D. farinae: 33.9%; D. pteronyssinus: 35.8%; American 
cockroach: 21.8% 
 
 
APT: higher specificity (69-92% depending on the 
allergen) than SPT (44-53%) and IgE levels (42-66%) 
 
48% of aeroallergen sensitized patients had a positive 
APT; this correlated highly significant with a positive 
LTT 
 
66.7% of cases with and 10.5% of cases without a 
predictive history of exacerbations during pollen 
season 
 
In a large cohort (n=1007 APT, 873 challenges), APT to 
food allergens added only a small predictive value to 
SPT and sIgE 
 
15/16 (94%) patients had a reproducible APT reaction 
 
Petrolatum as a vehicle and allergen concenrations of 
at least 1000 protein nitrogen units/ml give best 
outcome 
 
 
 
Positive APT reactions occur frequently in AD patients 
 
 
 
APT may be useful to diagnose clinically relevant 
sensitizations to inhalant allergens 
 
APT reactions are significantly correlated to allergen 
specific lymphocyte proliferation 
 
 
APT indicates clinically relevant positive reactions to 
inhalant allergens 
 
 
APT to food allergens is less robust compared to APT to 
inhalant allergens; higher specificity and lower 
sensitivity than SPT and sIgE 
 
APT results are highly reproducible 
 
 
Validity of APT reactions depends on vehicles and 
allergen concentrations 
 
 
 
Small cohort 
 
 
 
Clinical relevance mainly 
evaluated by history only 
 
 
 
 
 
Only investigated grass pollen, 
small cohort 
 
 
 
 
 
 
Small cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several studies with similar 
results, e.g. (1) 
 
 
 
 
 
 
(1) 
 
 
 
(2) 
 
 
(3) 
 
 
 
(4) 
 
 
 
(5) 
 
 
 
(6) 
 
 
(7) 
APT: immunological 
relevance 
 
 Reviewed in:  
 
   (8, 9) 
 
 
Th2 immunity 
 
 
 
 
 
 
 
 
Dynamics/kinetics of 
immune response 
 
 
 
 
 
 
 
 
 
Specificity 
 
Tissue cell culture from APT reactions 
(AD patients) 
 
Comparison of APT reactions to lesional 
AD in AD patients 
 
Gene expression in lesional APT skin 
(AD patients) 
 
Histology/ gene expression/ TCC from 
dust mite APT in AD patients 
 
Interaction of allergen and microbiota 
in AD patients 
 
 
Immune-histochemistry and flow 
cytometry of DCs in AD (n=66) 
compared to CD (n=12) 
 
APT in patients with co-existing 
psoriasis and AD (n=8) 
 
APT to autoantigens in AD patients 
 
APT reactions contain Der p specific Th2 cells 
 
 
Dust mite induces a Th2/Th9 skewing, but also 
Th17/Th22 activation 
 
APT to different food allergens induces Th2, Th17 
responses and IL-33 
 
Early APT reactions are mediated by Th2, while other 
T cell responses occur in the course of the reaction 
 
Superantigens cause increased APT reaction 
Superantigens induce IL-17 and IL-22 in APT reactions 
 
Inflammatory epidermal dendritic cells migrate early 
in APT reactions where they persist; FceRI is 
associated to extrinsic AD 
 
Dust mite induces a Th2 mediated eczematous 
reaction in sensitized psoriasis patients 
 
AD patients with T cell-mediated autoimmunity 
against manganese superoxide show APT reactivity 
 
 
APT can be used as a model for acute AD 
 
 
Reaction to dust mite does not fully reflect human AD, 
e.g. regarding barrier 
 
APT reflects a type 2 dominated immune response 
 
 
APT reflects acute immunity as well as later stages of AD 
immunity 
 
Microbial products influence AD 
 
 
 
APT is a useful model to investigate DC subtypes 
 
 
 
At least a subgroup of AD is caused by adaptive 
immunity 
 
Identification of manganese superoxide as autoantigen 
in AD 
 
 
Early proof of concept study 
 
 
n=15 
 
 
 
 
 
 
 
 
 
 
 
 
No functional analysis 
 
 
 
Special, small  cohort of 
patients 
 
Reproduced in several 
studies, also for other 
allergens 
 
 
 
 
 
 
Highly reproducible also 
for other allergens, e.g. 
(10, 11) 
Reproduced in (12) 
 
 
 
 
 
 
 
Reproduced in (13) 
 
 
Reproduced for  
Malassezia sympodialis 
thioredoxin (14) 
 
 
(15) 
 
 
(16) 
 
 
(17) 
 
 
(18) 
 
 
(19) 
(20, 
21) 
 
(22) 
 
 
 
(23) 
 
 
(24) 
Contact allergens System Interplay/ 
Application 
Key Findings Scientific Merit/ 
Clinical Relevance 
Limitations Reproducibility Refs. 
Patch testing: clinical 
usage 
 
 Reviewed in: 
 
   (25, 
26) 
 
 
Epidemiology 
 
 
Immunological 
relevance 
 
 
 
 
Patch tests to haptens in AD patients 
 
 
Patch tests to experimental haptens in 
AD patients 
 
 
Gene expression following patch tests 
 
AD patients with severe disease have lower 
prevalence of contact allergy. 
 
AD patients have attenuated ACD reactions compared 
to controls and in a severity-dependent manner. 
 
Nickel induces Th1/Th17 responses, fragrances induce 
a Th2/Th22 immune response 
 
Clinically relevant ACD in AD patients needs to be ruled 
out by patch testing.  
 
Immune bias in AD reduces the ability to amount a 
contact allergic response. 
 
 
Haptens induce distinct molecular profiles; some of 
 
No definite information about 
severity 
 
 
 
 
 
 
 
Reproduced in a large 
meta-analysis 
 
Highly reproducible, e.g. 
(27, 28) 
 
 
 
 
(29) 
 
 
(30) 
 
 
 
(31) 
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 to different haptens (n=24 ACD 
patients w/o AD) 
 
 
Patch tests in AD patients (n=18) and 
healthy volunteers (n=10) 
 
 
 
Repetitive application of hapten 
 
 
 
DNCB-specific immune responses in controls were 
Th1 dominated; Th1 immunity was less in AD, but 
here a specific and stable Th2 immunity was induced 
towards DNCB 
 
Repetitive hapten challenge caused a switch in 
immune response towards Th2 immunity including 
barrier damage 
them might mimic AD 
 
 
 
AD patients show a Th2 skewed ACD reaction 
 
 
 
 
Immune responses towards a hapten might change after 
repetitive challenge 
 
 
 
 
Small cohort (n=16 AD 
patients); experimental hapten 
 
 
 
Murine study 
 
 
 
 
 
 
 
 
 
 
(32) 
 
 
 
 
(33) 
 
 
Other challenge 
models 
System Interplay/ 
Application 
Key Findings Scientific Merit/ 
Clinical Relevance 
Limitations Reproducibility Refs. 
 
 
Aero-challenge 
 
 
Treatment 
Standardization 
 
 
 
 
 
Trigger challenge 
 
 
 
 
Pollen chamber challenge of sensitized 
AD patients 
 
Application of vehicles and/ or topical 
treatments in AD patients 
 
 
Application of petrolatum (n=13 AD 
patients, n=36 healthy volunteers) 
 
Application of established AD triggers 
(AD patients) 
 
 
AD patients sensitized to grass pollen reacted with 
worsening of AD symptoms and biomarkers 
 
Standardized application of different topical 
treatments, assessment of TSS, TEWL, and biomarkers 
 
Petrolatum enhances antimicrobial peptides and 
epidermal barrier genes 
 
Hard water increases IL-4, IL-10 and IFN-gamma   
 
 
IgE might play a role in AD 
 
 
Approach of standardized clinical assessment of topical 
treatments 
 
 
Barrier restoration might also repair immune 
abnormalities in AD 
 
Domestic hard water exposure during infancy increase 
risk of AD. 
 
 
No direct causal link to IgE 
 
 
 
 
 
 
No evidence for a specific effect 
of petrolatum 
 
Experimental design does not 
mimic real world exposure 
 
  
 
(34) 
 
 
(35) 
 
 
 
(36) 
 
 
(37) 
 
Abbreviations: APT: Atopy Patch Test; SPT: Skin Prick Test; LTT: Lymphocyte Transformation Test; ACD: allergic contact dermatitis; TSS: total sign score; TEWL: transepidermal water loss; DC: dendritic cell; CD: contact dermatitis 
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Supplementary Table 1. Human In vitro Models of AD 
2D Models System Interplay/Application Key Findings Scientific Merit/Clinical Relevance Limitations Ref 
Patient-derived cells EpidermisImmune AD HEK vs. NHEK: ↑GM-CSF ; conditioned media from AD keratinocytes induced PBMC 
proliferation 
GM-CSF associated with population-specific AD 
pathogenesis and severity (1-3) 
No epidermal characteristics assessed; small 
patient cohort (n = 8) 
(4) 
FLG knockdown (KD) BarrierImmune/Epidermal 
Differentiation 
NHEK: lentiviral KD; ↑Th2 cytokines: IL-2/4/5/13; ↓IFNγ; ↓KRTs, ↓IVL, ↓TGM1, ↑Lor FLG KD induces keratinocyte cytokine release 
(5); FLG changes are associated with AD 
No assessment of lipids or barrier function; no 
rescue experiment 
(6) 
IL-4/IL-13 treatment ImmuneBarrier NHEK: ↓FLG mRNA and protein Cytokines known to drive AD No epidermal characteristics assessed (7) 
AD drug discovery 
model 
Barrier Compound library screened by FLG reporter assay in HaCaT cells; NHEK: ↑ FLG mRNA and 
promoter activity by compound JTC801; ↑FLG in 3D and explant cultures 
JTC801 ↑FLG and suppressed AD-like 
phenotype in NC/Nga mice 
Only FLG taken into consideration as a target (8) 
Immune cells only Immune TSLP receptor is increased in AD-derived skin-associated Th2 cells; TSLP increases IL-4 
producing T-cells 
TSLP highly expressed in AD keratinocytes and 
known to trigger dendritic cells (9) 
No epidermal component (10) 
3D Models System Interplay/Application Key Findings Scientific Merit/Clinical Relevance Limitations Ref 
FLG KD Models   FLG is relevant in pathogenesis of AD (11) FLG loss associated with 20-50% of AD (12); 
FLG KD does not always cause AD-like 
phenotype in vitro (13, 14) 
 
Human epidermal 
equivalent (HEE)
a
 
BarrierImmune/Epidermal 
Differentiation 
NHEK: lentiviral shRNA KD; epidermal thickening; FLG loss associated with changes in 
proteases, inflammatory, and stress-related pathways based on proteomic profiling 
Findings validated in AD patient samples; data 
can enhance systems biology modeling of AD 
No evidence changes in protein expression 
underlie AD phenotype 
(15) 
BarrierEpidermal 
Differentiation 
NHEK: lentiviral shRNA KD; hypogranulosis; ↓corneodesmosomes; ↓NMF; ↑barrier 
permeability; ↑UV sensiDvity; altered diﬀerenDaDon 
FLG loss is clinically associated with barrier 
dysfunction; similar results with FLG2 KD (16) 
Epidermal thinning; immune component not 
assessed; no rescue experiment 
(17) 
 
Human skin 
equivalent (HSE)
b
 
BarrierEpidermal 
Differentiation 
NHEK: siRNA KD; hypogranulosis; ↑barrier permeability; ↑UV sensitivity FLG loss is clinically associated with barrier 
dysfunction; siRNA produced similar phenotype 
in other studies (18-20) 
↔differentiation or lipid synthesis; immune 
component not assessed; no rescue 
experiment 
(21) 
FLG KD + IL-4/IL-13 
HSE 
BarrierImmune/Epidermal 
Differentiation 
NHEK: siRNA KD; spongiosis, ↑proliferaDon; ↑epidermal thickness; ↓IVL; ↓LOR; ↓OCLN; 
↑TSLP; ↑DEFB4A 
Combination of FLG loss and immune activation Barrier function not assessed; no rescue 
experiment 
(22) 
Co-culture Models   Multiple systems contribute to AD   
CD45RO+ T-cell HSE EpidermisImmune HaCaT: spongiosis; ↑apoptosis; ↓TEER; ↑cytokine release; ↑ICAM-1; ↑NT-4 Activated T-cells drive AD; dexamethasone or 
tacrolimus reversed 3D model phenotype 
Primary keratinocytes not used 
 
(23) 
 
FLG KD + CD4+ T-cell ImmuneEpidermis 
Immune 
NHEK: siRNA KD; ↑IL-8 and IL-6 secretion; ↑skin surface pH; ↓ IVL; ↑barrier 
permeability; ↑TSLP; ↑T-cell migration; CD4+ T-cells shift to Th2/Th22  
TSLP-dependent T-cell migration indicates direct 
T-cell/keratinocyte cross-talk 
No histological changes vs. FLG KD without T-
cells 
(24) 
AD cell-derived HSE DermisEpidermisDermis 
 
Healthy NHEK + AD Fibroblasts: ↓FLG/FLG mRNA; ↓KRT10; epidermal thickening  
AD HEK + Healthy Fibroblasts: rescues FLG, KRT10, KRT5 
Fibroblasts may mediate immune cell 
infiltration in skin (25) 
Immune component and barrier not assessed; 
AD patient samples with variable FLG status;  
(26) 
 
Nerve HSE NeuronsEpidermis NHEK: Innervated cultures alone or with substance P+CGRP neuropeptides ↑epidermal 
thickness and ↑ Ki67; AD HEK vs. NHEK: ↑innervaDon; ↑ epidermal thickness 
Increased nerve fibers in AD (27); used for drug 
discovery of neuron-modulating agents (28) 
Immune component and barrier not assessed; 
porcine dorsal root ganglia used for neurons 
(29) 
Cytokine Models   Immune modulators are relevant to AD   
IL-4-treated HSE ImmuneEpidermal 
Differentiation 
N/TERT: ↑proliferaDon; ↓KRT10; ↓IVL; suprabasal integrin-β1 Assesses the effects of a single cytokine; similar 
effects on proliferation in NHEK (30) 
Primary keratinocytes not used; IL-4 alone 
shown not reduce FLG in NHEK (30) 
(31) 
IL-4/IL-13-treated 
HSE 
ImmuneBarrier 
 
NHEK: spongiosis; ↑apoptosis; ↑phosphorylated STAT6; ↑CA2 mRNA; ↑NELL2 mRNA 
 
mRNA levels matched AD biopsies 
No change in psoriasis-associated genes 
Barrier not assessed; dexamethasone or 
tacrolimus did not reverse phenotype 
(32) 
 
IL-17-treated HSE Immune Barrier/ 
Epidermal Differentiation 
NHEK: ↓TEER; ↑barrier permeability; ↓TJ proteins; SC thickening; Δ in FLG and LOR 
localization 
Loss of TJ proteins confirmed in small cohorts of 
normal and AD patients 
Changes in keratinocyte immune signaling not 
assessed 
(33) 
 
IL-31RA expression + 
IL-31-treated HSE 
ImmuneEpidermal 
Differentiation 
HaCaT: ↓FLG
†
; ↓desmosomal transcripts*; ↓CASP14 mRNA*; ↓ CDSN mRNA; ↔ TJ 
proteins; ↑barrier permeability; ↑IL-1α release*   
NHEK: ↓FLG; ↑anDmicrobial pepDdes 
IL-31 expression associated with AD (34); similar 
effects seen in HaCaT cells (35) 
 
Most experiments performed with HaCaT cells (36) 
 
Cytokine cocktail-
treated HEEs 
ImmuneEpidermal 
Differentiation 
 
NHEK: Cocktail: poly(I)C, TNFα, IL-4, IL-13 
↓FLG/FLG mRNA; altered differentiation and inflammation; ↑TSLP and ↑IL-8 secretion 
Transcriptomic profiling after cocktail correlates 
with AD datasets; ↓FLG with TNFα/IL-4, IL-13, 
IL-22 cocktail (37) 
Barrier function not assessed 
 
(38) 
 
NHEK: Cocktail: IL-4, IL-13, IL-25 with or without methyl-β-cyclodextrin (disrupts lipid rafts) 
hypogranulosis; spongiosis; ↓TEER; ↓FLG mRNA; ↓LOR/LOR mRNA; ↑ CA2/CA2 mRNA; 
↑NELL2 mRNA 
Effect on protein expression by cocktail 
treatment correlated with AD patient samples;  
Role of membrane lipid domains not clear in 
AD; no change in keratinocyte TSLP 
(39, 
40) 
 
NHEK: Cocktail: TNFα, IL-4, IL-13, IL-31  
spongiosis; ↑proliferaDon; altered differentiation; ↑TSLP; ↓faNy acids; ↓ceramides 
Tested cytokines alone and in combination Barrier function not assessed 
 
(30) 
 
ILs and HMGB HSE 
and HEE 
ImmuneImmune/Epidermal 
Differentiation 
NHEK*: ↑epidermal alarmins (IL-33 and HMGB1) with IL-25+IFNγ; IL-25, IL-33, IL-4, or 
HMGB1 treatment ↓FLG/FLG mRNA; ↓IVL; ↓LOR; ↑proliferaDon 
Effects seen in 3 epidermal culture models epidermal thinning; barrier function not 
assessed 
(41) 
Allergy  Models      
Histamine  treatment 
HEE 
Immune Barrier/Epidermal 
Differentiation 
NHEK: ↓ FLG/FLG mRNA*; ↓LOR/LOR mRNA*; ↓KRT10/KRT10 mRNA*; ↓DSG1; CDSN; 
↓TJ proteins; ↑barrier permeability 
Histamine mediates mast cells which are 
correlated to inflamed skin (42) 
No change in histamine-treated explant 
cultures 
(43) 
 
Explant Models      
Patient samples AD vs. normal tissue In AD explants: ↓LOR; ↓IVL; ↓desquamaDon enzymes Explants maintain AD biopsy phenotypes  Barrier function not assessed; no system 
perturbations 
(44) 
 
Cytokine cocktail ImmuneSkinImmune Cocktail: IL-4, IL-5, IL-13, TNFα; ↑TSLP release;↑IL-8; induction of dendritic cell 
maturation 
Use of skin explants and epidermal explants; 
TSLP release relevant to AD (9) 
AD skin samples not used; barrier function or 
differentiation status not tested 
(45) 
a, epidermal equivalents are 3D cultures with only keratinocytes; b, skin equivalents are 3D cultures with components of the dermis, e.g., collagen lattice and/or fibroblasts; ↑: increase, ↓: decrease, ↔: no change; *, effects observed in 2D cultures of the same 
cell type; †, eﬀect observed in explant culture 
Abbreviations: AP-1: activator protein 1; CGRP: calcitonin gene-related peptide, CAII: carbonic anhydrase II, CASP14: caspase 14, CDSN: cormeodesmin, DSG1: desmoglein 1 FLG: filaggrin, GM-CSF, granulocyte-macrophage colony-stimulating factor, HMGB1: high-
mobility group box 1, ICAM-1: intracellular adhesion molecule 1, IFN: interferon, IL: interleukin, IVL: involucrin, KRT: keratin, LOR: loricrin, NELL2: neural epidermal growth factor–like 2, NHEK/HEK: normal human epidermal keratinocytes (primary), NMF: natural 
moisturizing factor, NT-4: neurotrophin 4 PBMC: peripheral blood mononuclear cell, STAT6: signal transducer and activator of transcription 6, TJ: tight junction, TEER: transepithelial electrical resistance, TGM1: transglutaminase 1, TSLP: thymic stromal 
lymphopoietin 
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